ImmunoScience INDIA

ImmunoELISA HIV 1 + 2

"ELISA Assay for Detection of HIV 1 and HIV 2 Antibodies in human serum or Plasma"

Store at 2 °C to 8 °C

SUMMARY OF TEST:

Human immunodeficiency virus type I and type II (HIV 1+2) are enveloped single strain RNA positive virus. The causative relationship between HIV 1+2 virus and acquired immunodeficiency syndrome (AIDS) has been established over decades. HIV-1 has been isolated from patients with AIDS and AIDS-related complex, and from healthy individuals with a high risk for developing AIDS. HIV-2 has been isolated from West African AIDS patients and from seropositive asymptomatic individuals. Infection with HIV induces the immune system to produce antibodies against viral proteins from different parts of the HIV genome, ENV, GAG and POL. Diagnosis of anti-HIV sero-positivity is based on the detection of these specific antibodies. HIV antigen is produced during the viral replication phase and generally appears some days after exposure then decreases quickly as antibodies are being produced. Years later, antigenemia may again increase, and is indicative of intense viral replication. Kits to detect markers of HIV infection have been available since 1985.



INTENDED USE:

The **ImmunoELISA HIV 1 + 2** is a solid phase enzyme linked immunosorbent assay for the qualitative detection of Anti- HIV-1 including subtype O and anti-HIV-2 antibodies (including isotope IgG, IgM and IgA) in human serum or plasma. It is intended for professional use only as an aid in the identification & diagnosis of infection with HIV-1 and HIV-2 viruses. It is also intended for use as a donor screening test to detect antibodies to HIV in plasma and serum samples from individual human donors, including volunteer donors of Whole Blood, blood components, source plasma, and other living donors. Any reactive specimen with the **ImmunoELISA HIV 1+ 2** ELISA Kit must be confirmed with alternative testing method(s) and correlate with clinical findings.

PRINCIPLE OF THE TEST:

Recombinant HIV-1 and HIV-2 antigens are adsorbed onto the wells of the micro assay plate. The wells are coated with recombinant HIV-1 gp41 antigen, recombinant HIV-1 group O gp41 antigen and recombinant HIV-2 group gp36 antigen.

Serum or plasma samples are added to these wells. If antibodies to HIV-1/HIV-2 are present in the sample, they will form stable complexes with the HIV-1 and HIV-2 antigen on the plate.

A recombinant HIV-1 gp 41 antigen/ peroxidase conjugate, recombinant HIV-1 group O gp 41 antigen/ peroxidase conjugate recombinant HIV-2 gp 36 antigen/peroxidase conjugate is added. If the antigen/antibody complex is present, the peroxidase conjugate will bind to Antibody, antigen and remain in the well.

Enzyme substrate is then added. The colour will change in wells containing Antibody-Antigen Complex. An acidic stop solution is added to each well and the colour is read on the photometer at 450 nm. A reference wavelength of 630 nm is recommended.

KIT COMPONENTS (1 X 96 TEST)

1. **Microwell plate (1x96 wells)**: Each well coated with recombinant HIV-1 and HIV-2 antigens in Carbonate- bicarbonate buffer (solvent).
2. **Specimen/Sample Diluent (1 x 20 ml):** One bottle contains Phosphate buffer saline, Triton-X -100 (as surfactant), Bovine serum albumin (protein stabilizer) and Proclin-300 (as preservative) 0.1% v/v.
3. **Negative Control: (1x 0.5 ml):** One bottle contains normal human serum and Proclin-300, 0.1% v/v as preservative.
4. **Positive Control: (1x 0.5 ml):** One bottle contains inactivated anti-HIV human serum and Proclin-300 0.1% v/v as preservative.
5. **HIV specific HRP Conjugate concentrate, 101x (1x 0.3 ml)**: one bottle contains recombinant HIV-1 and HIV-2 antigen/peroxidase conjugate, Bovine serum albumin (as stabilizer) and gentamycin sulphate 0.005% and Proclin-300, 0.05% v/v (as preservative).
6. **Conjugate Diluent (1x 20 ml)**: one bottle contains phosphate saline-casein buffer and Proclin-300 0.05% v/v (as preservative).
7. **TMB Substrate, 101x concentrated (1x0.3 ml)**: one bottle contains tetramethyl benzidine in Dimethyl sulphoxide as solvent.
8. **Substrate Buffer (1x20ml)**: one bottle contains Citrate-Acetate buffer (solvent) containing hydrogen peroxide 0.006% v/v.
9. **Wash Buffer concentrate 20x (1x50ml)**: one bottle contains concentrated phosphate buffered saline with polysorbate (surfactant) and Proclin-300 (preservative), 0.05 %v/v.
10. **Stop Solution (1x20ml)**: one bottle contains 1.5 N sulphuric acid.
11. **Instruction manual/product Insert.**

MATERIALS REQUIRED BUT NOT PROVIDED:

1. Micro pipette capable of delivering 10 µl, 50 µl, 75 µl, and 100 µl volumes with a precision better than 1.5%.
2. Microplate reader with a bandwidth of 10 nm or less and an optical density range of 0-3 OD or greater at 450 nm wavelength is acceptable
3. Absorbent paper for blotting the microplate wells
4. Parafilm or other adhesive film sealant for sealing plate
5. Timer
6. Distilled or de-ionized water.

SPECIMEN COLLECTION AND REPARATION:

1. Serum or plasma should be prepared from a whole blood specimen obtained by acceptable venipuncture technique.
2. This kit is designed for use with serum or plasma specimen without additives only.
3. If a specimen is not tested immediately, the serum/plasma shall be separated and refrigerated at 2°C - 8°C. If storage period greater than three days are anticipated, the separated serum/plasma should be frozen (-20°C).
4. Avoid repeated freezing-thawing of specimens.
5. If a specimen is to be shipped, pack in compliance with federal regulation covering the transportation of etiologic agents.
6. Specimens containing precipitants may give inconsistent test results. Clarify such specimens by centrifugation prior to assaying.
7. Do not use serum specimens demonstrating gross lipemic or lipemia, gross hemolysis or turbidity.

8. Do not use specimens containing sodium azide as preservative.

REAGENT PREPARATION

A. Wash Buffer preparation: Dilute 20x wash buffer provided in the kit in 1: 20 ratios in purified water. For example, to prepare 1000 ml wash buffer, mix 50 ml of 20x wash buffer into 950 ml of purified water. Decide the volume of buffer according to the required number of test and dead volume of washer instrument. In case of manual washing, the volume can be calculated accordingly.

B. HRP Conjugate preparation: Dilute HRP conjugate concentrate (101x) in conjugate Diluent (1:101 ratio) as follows:

Strips	1	2	3	4	5	6
HRP C. 101x (µl)	10	20	30	40	50	60
Conj. Diluent (ml)	1	2	3	4	5	6

Strips	7	8	9	10	11	12
HRP C. 101x (µl)	70	80	90	100	110	120
Conj. Diluent (ml)	7	8	9	10	11	12

C. TMB substrate preparation: Dilute TMB substrate concentrate (101x) in Substrate Buffer (1:101 ratio) as follows:

Strips	1	2	3	4	5	6
TMB S. 101x (µl)	10	20	30	40	50	60
Substrate Buffer (ml)	1	2	3	4	5	6

Strips	7	8	9	10	11	12
TMB S. 101x (µl)	70	80	90	100	110	120
Substrate Buffer (ml)	7	8	9	10	11	12

- ✓ Prepare the reagents just before use.
- ✓ Prepare only the required quantity of reagents.
- ✓ Ensure the TMB substrate to be kept in low light and closed container.
- ✓ Discard the remaining reagent after use.

ASSAY PROCEDURE

1. Take the required number of strips and fix them to plate.
2. Pipette 100 µl of sample diluent into each plate well and pipette 10 µl of Negative control into each well from 1A to 1C and 10 µl of Positive Control into each well from 1D to 1E, respectively and then, pipette 10µl of each specimen into the remaining well.
3. Mix the added samples manually or by using microplate shaker, take care not to mix or splash contents out of well while mixing.
4. Seal the microwell strips using the plate cover and incubate at 37°C ± 1°C for 30 minutes.
5. Before 5 to 10 minutes of completion of the 1st incubation, make 1:101 dilution of HRP conjugate with conjugate diluent.
6. Aspirate the contents from all the wells and wash 5 times with 300 to 350 µl of diluted washing solution. (325 µl/well/time)
7. Invert the plate and tap it on absorbent paper to remove the remaining wash solution, and then, pipette 100 µl of prepared diluted HRP conjugate into each well.
8. Incubate at 37°C ± 1°C for 30 minutes after sealing the plate with cover.
9. Before 5 to 10 minutes of 2nd incubation, make 1:101 dilution of TMB substrate with substrate buffer.
10. Aspirate the contents from all the wells and wash 5 times with 300 to 350 µl of diluted washing solution. (325 µl/well/time)
11. Invert the plate and tap it on absorbent paper to remove the remaining wash solution, and then, pipette 100 µl of prepared diluted TMB substrate into each well. And incubate at controlled room temperature (21°C - 25°C) in dark environment for 30 minutes.
12. Pipette 100 µl of stop solution into each well and tap the plate gently to homogenize the coloring materials.
13. Read the absorbance at 450 nm (reference wavelength at 630 nm) against an air blank within 30 minutes after pipetting of stop solution.

QUALITY CONTROL

1. The average absorbance of Positive Control (PCx) should be greater than or equal to 1.0.
2. The average absorbance of Negative Control (NCx) should be less than or equal to 0.200.

INTERPRETATION OF RESULTS

(a) Calculate the negative control mean(NCx)
Ex. Negative Control 1 absorbance=0.045
Negative Control 2 absorbance=0.050
Negative Control 3 absorbance=0.055
Negative Control Mean (NCx)=
(0.045+0.050+0.055)/3=0.050

(b) **Calculate the positive control mean (PCx)**
Ex. Positive Control 1 absorbance=1.573
Positive Control 2 absorbance=1.525
Positive Control Mean (PCx)= (1.573+1.525)/2=1.549

(c) Calculate the cut off value
Cut off value= NCx + 0.200

INTERPRETATION

Samples with absorbance greater than or equal to the Cut Off value are considered positive to anti-HIV-1/2. Samples with absorbance less than Cut Off value are considered negative to Anti-HIV-1/2. Sample values within the ±10% of cut off value should be considered as indeterminate or grey zone samples. It should be retested again or repeat with fresh collected sample.

WARNING AND PRECAUTIONS:

1. This product is made for in Vitro Diagnostic Use only.
2. Package insert must be read completely before performing the test. Failure to follow the instructions in pack insert may give inaccurate test results.
3. Do not use the Kit beyond the expiry date.
4. Bring all reagents & samples to room temperature (18°C-28°C) before use.
5. Do not use the components in any other type of test kit as a substitute for the components in this kit.
6. Do not use hemolyzed blood specimen for testing.
7. Do not ingest the reagents. Avoid contact with eyes, skin and mucose. Wear protective clothing and disposable gloves while handling the kit reagents and clinical specimens. Wash hands thoroughly after performing the test.
8. Do not smoke, drink, or eat in areas where specimens or kit reagents are being handled.

9. Users of this test should follow the US CDC Universal Precautions for prevention of transmission of HIV, HBV and other blood-borne pathogens.
10. Dispose of all specimens and materials used to perform the test as bio-hazardous waste.
11. In the beginning of each incubation and after adding stop solution, gently rocking the microwells to ensure thorough mixing. Avoid the formation of air bubbles as it may give inaccurate absorbance values. Avoid splash liquid while rocking or shaking the wells.
12. Don't allow the micro plate to dry between the end of the washing operation and the reagent distribution.
13. The enzyme reaction is very sensitive to metal ions. Thus, do not allow any metal element to come into contact with the conjugate or substrate solution.
14. The TMB substrate solution must be colorless. The appearance of color indicates that the reagent cannot be used and must be replaced. The TMB Substrate must be stored in the dark.
15. Use a new distribution tip for each specimen. Never use the specimen container to distribute conjugate and substrate.
16. The wash procedure is critical. Wells must be aspirated completely before adding the Washing Solution or liquid reagents. Insufficient washing will result in poor precision and falsely elevated absorbance.
17. Avoid strong light or sunlight during color development.

LIMITATIONS:

1. The **ImmunoELISA HIV 1 + 2** is intended to detect antibodies against HIV 1 and HIV 2. However, the test cannot detect the quantity or relative change in the levels of antibodies.
2. The product is not made for detection of HIV 1/HIV 2 Antigen.
3. The product is designed so as to give best results but, some samples may show cross reactivity. Hence, there may be a chance of false positive results. Every positive result shall be verified by testing with alternate kit or methods and also shall be correlated with symptoms.

REFERENCES:

1. Leligdowicz A, Yindom L-M, Onyango C, et al. (2007) Robust Gag-specific T cell responses characterize viremia control in HIV-2 infection. J. Clin. Invest. 117(10):3067-3074.
2. Cohen, MS; Hellmann, N; Levy, JA; DeCock, K; Lange, J (2008). "The spread, treatment, and prevention of HIV-1: evolution of a global pandemic". The Journal of Clinical Investigation118 (4): 1244–54.
3. Tao G, Branson BM, Kassler WJ, Cohen RA. (1999) Rates of Receiving HIV Test Results: Data From the U.S. National Health Interview Survey for 1994 and 1995. JAIDS Journal of Acquired Immune Deficiency Syndromes. 22(4).
4. Guyader, M., Emerman, M., Sonigo, P., et al. Genome organization and transactivation of the human immunodeficiency virus type 2. Nature 326:662-669, 1987.
5. Blattner, W., Gallo, R.C., and Temin, H.M. HIV causes AIDS. Science 241:515, 1988.
6. Curran, J.W., Morgan, W.M., Hardy, A.M., et al. The epidemiology of AIDS; Current status and future prospects. Science 229:1352-1357, 1985
7. Sarngadharan, M.G., Popovic, M., Bruch, L., Schüpback, J., and Gallo, R.C. Antibodies reactive with human T-lymphotropic retroviruses (HTLV-III) in the serum of patients with AIDS. Science 224:506-508,1984.
8. Gallo, R.C., Salahuddin, S.Z., Popovic, M., et al. Frequent detection and isolation of cytopathic retroviruses (HTLV-III) from patients with AIDS and at risk for AIDS. Science 224:500-503, 1984 6. Weber, J.N., Weiss, R.A., Roberts, C., et al. Human immunodeficiency virus in two cohorts of homosexual men; Neutralising sera and association of anti-gag antibody with prognosis. Lancet 1:119-124, 1987
9. Clavel, F., Gu(tard, D., Brun-V(zinet, F., et al. Isolation of a new human retrovirus from West African patient with AIDS. Science 233:343-346, 1986.

IVD	In Vitro Diagnostic Use
	Manufacturer
	Manufacturing Date
	Expiry Date
LOT	Lot Number
	Store at + 2°C to + 8°C
	Single Use
	Number of tests in the pack
	Do not use if pouch or kit damaged
	This side Up
	Read package insert beforeuse

MANUFACTURED BY

ImmunoScience India Private Limited,
Gat No. 41, Kusgaon, Shivapur-Velhe Road,
Tal- Bhor, Pune, Maharashtra (India) – 412205.